Skip to main content

Jose Miguel Lizcano De Vega

I am Professor (Full) of Biochemistry at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

Institutions of which they are part

Head of group
Protein kinases in cancer research
Vall Hebron Institut de Recerca

Jose Miguel Lizcano De Vega

Institutions of which they are part

Head of group
Protein kinases in cancer research
Vall Hebron Institut de Recerca

I am Professor (Full) of Biochemistry at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

I graduated in Biochemistry at the Universitat Autònoma de Barcelona (UAB). After obtaining a PhD in Biochemistry and Molecular Biology (Neurochemistry) at the UAB, I made a first postdoctoral stay at the Department of Biochemistry at Trinity College Dublin (1995-96), working on Molecular Pharmacology. In 1998, I joined the MRC Protein Phosphorylation Unit (Dundee, UK), where I specialized in the study of protein kinases and cellular signaling, and in their alteration in diseases such as diabetes and cancer.

In 2004, I joined the Institute of Neurosciences UAB as a Ramón y Cajal researcher. Since 2005, I am Associate Professor at the UAB Department of Biochemistry of the Faculty of Medicine. I founded the Cell Signaling group, which studies the role of protein kinases in degenerative processes such as neurodegenerative diseases and cancer. Since 2010, my interest has focused on the study of cell signaling alterations in cancer, and on the preclinical development of new antitumor drugs. I have been vice-director of the Department of Biochemistry and director of the Biochemistry Unit of the Faculty of Medicine of the UAB.

In 2021 I joined the VHIR Institute, to lead the Laboratory of Protein Kinases and Cancer, which I combine with my teaching activity on the UAB campus. The ultimate goal of my research is to understand the biochemical basis of the tumor cell, in order to develop new molecular therapies that improve the survival and quality of life of cancer patients.

Projects

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán , Nora Diéguez Martínez, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, María de los Ángeles Rodríguez Sánchez, Maria Luz Uria Oficialdegui , Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Raquel Anta Peña, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia , Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Gabriel Osvaldo Gallo , Elena Andretta , Roberta Antonelli , Claire Diot , Amira Idrizovic
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 60000
Reference: 2021 SGR 00638
Duration: 01/01/2022 - 31/12/2024

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 18/10/2022

Ministerio de Ciencia

Related news

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

Inhibition of the ERK5 protein kinase reduces the proliferation and survival of endometrial cancer cells, and potentiates standard chemotherapy.

Related professionals

Laura Zalba Jadraque

Laura Zalba Jadraque

Predoctoral researcher
Peripheral Nervous System
Read more
Lydia Dux-Santoy Hurtado

Lydia Dux-Santoy Hurtado

Research technician
Cardiovascular Diseases
Read more
Jesus Manuel Rivera Esteban

Jesus Manuel Rivera Esteban

Predoctoral researcher
Liver Diseases
Read more
Breogan Rodriguez Acevedo

Breogan Rodriguez Acevedo

Senior researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.